IRADIMED CORP Q3 FY2026 earnings call

• Production Ramp Success: The launch of the new 3870 MRIV pump exceeded expectations, with over 400 units produced in Q3, marking a >125% sequential increase from Q2. The team successfully navigated complex electromechanical manufacturing challenges.
• Strong Backlog and Demand: A significant backlog has formed due to high customer acceptance. Over 300 pumps were shipped in Q3. The replacement cycle for older 3860 systems is accelerating, with ~70% of replacements opting for quad-stack configurations, creating a multi-year opportunity for >10,000 unit sales.
• Higher ASP and Greenfield Penetration: The average selling price (ASP) for the 3870 is nearly $25,000 per channel, a 23-25% lift over the older model. The new design’s user interface and automation have attracted 'greenfield' customers who previously rejected the older 3860 or used competing non-MRI pumps.
• Monitor Growth: Despite concerns that the new pump might cannibalize monitor sales, the 3880 monitor achieved record bookings in Q3. Enhancements include expanded wireless remote capabilities for control room monitoring.
• Margin Improvement: Gross margin improved two percentage points sequentially to 76%, as manufacturing efficiencies began to materialize on the learning curve for the 3870 production.

The company reported record total revenue of $24.2 million, representing a 14% year-over-year increase and an 18% sequential increase from Q2. The Pumper segment generated $8.7 million in revenue (up 4% YoY), driven by the ramping production of the new 3870 MRIV pump. MRI-compatible patient vital signs monitoring systems contributed $8.0 million (up 17% YoY), with bookings reaching record levels. Ferromagnetic detection systems contributed $0.5 million (up 28%). Recurring revenue streams also showed strong growth: disposables reached $5.0 million (up 21%), amortization of extended maintenance agreements grew to $0.8 million (up 31%), and Services & Other increased to $1.2 million (up 42%). In terms of geographic contribution, domestic sales accounted for 82% of total revenue ($19.7 million, up 9% YoY), while international revenue contributed 18% ($4.5 million, up 45% YoY).

• Q4 2026 Revenue Guidance: Expected between $25.0 million and $26.5 million.
• Q4 2026 EPS Guidance: GAAP diluted EPS expected between $0.53 and $0.57; Non-GAAP diluted EPS expected between $0.57 and $0.61.
• Full Year 2026 Revenue Guidance: Updated downward to $91.7 million–$93.2 million (prior range: $91.0 million–$96.0 million).
• Full Year 2026 EPS Guidance: GAAP diluted EPS updated to $1.90–$1.94 (prior: $1.90–$2.05); Non-GAAP diluted EPS updated to $2.06–$2.10 (prior: $2.06–$2.21).
• Rationale for Revision: The downward revision reflects the need to throttle production ramp rates slightly to maintain quality standards, preventing excessively high growth that could compromise product integrity.

• Manufacturing Quality vs. Speed: Aggressive production ramp rates carry the risk of slipping quality if not carefully managed; management explicitly stated they must 'throttle' growth to preserve quality.
• Tax Rate Volatility: The effective tax rate is currently elevated (~24.9%) compared to historical norms due to lower-than-anticipated windfall deductions from equity grant vesting.
• International Margin Pressure: International sales are lower-margin due to distributor discounts; fluctuations in the mix between domestic and international sales can negatively impact overall gross margins.
• Delayed Disposable Uptake: While hardware shipments are high, the corresponding increase in disposable revenue (IV sets) is lagging because new installations require 6-8 weeks for inservicing before usage ramps up.

Q: Why was full-year revenue guidance revised down despite record bookings? / A: CEO Roger Susi explained that while the production ramp was impressive (>125% sequential growth), pushing it too hard risks compromising quality. To ensure the 3870 pump maintains high standards, management decided to 'throttle' the output slightly rather than risking a quality slip. This prudent approach required reducing the upper end of the annual revenue forecast by approximately $3 million to reflect a more sustainable, albeit still strong, growth trajectory that balances volume with manufacturing integrity.

Q: How should investors view 2027 pump revenue potential given slowing quarter-over-quarter growth rates? / A: Management clarified that while the explosive % growth in unit volume will moderate from 2026's double-digit leaps, absolute revenue growth will remain robust. They expect upper-teens percentage growth in 2027, driven by higher ASPs ($25k/channel) and the transition to quad-stack configurations. Additionally, disposable revenue pull-through will begin compounding as the installed base matures, supporting continued top-line expansion that management views as competitive with peers.

Q: What drove the success in capturing 'greenfield' customers who previously rejected the 3860? / A: The new 3870 addresses key usability flaws of the 2005-era 3860. It features a modernized user interface, intelligent sensors, and on-screen animations that reduce user fear and training barriers. Crucially, its design mimics popular non-MRI IV pumps used elsewhere in hospitals, making it easier for staff to adopt. This familiarity, combined with automated safety features, convinced facilities that had ignored or underutilized the old system to switch to the new platform.

Q: What is the outlook for gross margins beyond Q4 2026? / A: CFO Jack Glenn expects Q4 margins to improve further upon the current 76% level. Looking ahead to early 2027, he anticipates margins returning to historical highs of 77-78% or better. This improvement is supported by two factors: increasing operational efficiency as the 3870 production stabilizes and the favorable impact of higher ASPs, particularly from selling quad-stack systems valued at over $100,000 each.